Scientists have developed a cancer cell-targeting strategy that can drive effective tumor inhibition while reducing off-target effects, a key limitation of conventional therapies.
Breakthrough in Targeted Gene Therapy
In a paper published in the journal Advanced Healthcare Materials, a team from the Agharkar Research Institute (ARI) in Pune described a biodegradable nanocarrier platform engineered for targeted gene therapy in breast cancer. The targeting system is built on biodegradable mesoporous silica nanoparticles, known for their high loading capacity and tunable surface chemistry, which enable efficient delivery of small interfering RNA (siRNA) molecules. These siRNA molecules prevent the production of disease-causing proteins.
Mechanism of Action
The siRNA molecules are delivered against two critical genes that promote tumor survival and resistance to therapy. A controlled release of the therapeutic payload inside the tumor microenvironment ensures efficient intracellular delivery and activity, the team explained. Experiments in breast cancer models demonstrated robust gene knockdown, resulting in increased cancer cell death and substantial inhibition of tumor growth.
Preclinical Success
In mice with a form of immunodeficiency, the nanocarrier accumulated effectively at tumor sites and exhibited minimal systemic toxicity. The findings align with growing evidence that aptamer-guided nanocarriers—a targeted drug delivery system using nanoparticles as vehicles—can significantly improve tumor specificity and therapeutic efficacy.
The researchers stated, "These results indicate that the biodegradable siMCL-1/siSur@MPPM nanocarrier provides a significant combination of targeted delivery, biodegradability, effective gene silencing, and reduced off-target effects, suggesting its potential as a promising nanomedicine for breast cancer treatment."
